Actually Cacaito, Vivus went up after FDA approval. It got to around 81, which split adjusted would be 40 1/2. It began going down after it hit the market and reports of marginal efficacy began circulating. Then they had a problem with an FDA review of their manufacturing facility. The stock came back as Muse seemed to find its niche, althiough now, Vivus seems to be pulling back based on earnings not meeting the whisper numbers. Even if a similar scenario should develop for Zonagen, it is probably more than a year away.
Zonagen does have minor sales via a subsidiary called Fertility Technologies Inc., so saying they have "not a single cent of sales" is untrue. Whether its current valuation is "huge" is a matter of opinion.
<< I do hope that Von Emster is buying at this moment, and not dumping while someone else load.>>
If you have proof of this, please present it, otherwise, why question this person's integrity in such a backhanded way?
As for Mexico, the company made a strategic decision to try to make a single deal with a major pharma rather than sell rights to specific geographic areas. In the long run, that is probably the most sensible way to go. Given Zona's price action, I doubt that any shareholders mind.
Good luck. |
